Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 4

Ustekinumab: differential use in psoriasis

Authors Uhlenhake E, Mehregan D

Published 1 July 2011 Volume 2011:4 Pages 93—99

DOI https://doi.org/10.2147/CCID.S17917

Review by Single-blind

Peer reviewer comments 3


Elizabeth E Uhlenhake, David A Mehregan
Wayne State University Department of Dermatology, Wayne State University School of Medicine, Detroit, MI, USA

Abstract: Chronic plaque psoriasis is a systemic disease affecting over 3% of the population, and many patients are unsatisfied with their current treatment regimen. With advances in understanding of the pathophysiology of psoriasis, new therapeutic options are being developed. The newest of these agents, ustekinumab, offers patients rapid results and the convenience of four annual subcutaneous doses, with efficacy and safety profiles comparable with those of other biologics. However, ustekinumab has been on the market in the US for less than 2 years and will require years of extensive use before the full adverse event profile is fully understood. The purpose of this paper is to summarize the treatment options currently available for psoriasis, with an emphasis on ustekinumab in order to give prescribers an overview of the available data and allow them to make educated and informed prescribing decisions.

Keywords: psoriasis, treatment, ustekinumab, safety, biologics

A Letter to the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]